Are we getting an opportunity now to buy ResMed?
The share price of ResMed (RMD) has shed almost 10 per cent since the start of August. It’s now trading on a P/E of ~20x, compared to ~24x around the time of their fiscal year result. There are however some concerns in the market about an expected impact on gross margins from pricing pressure from its US customers. Looking at the chart, we are can also identify some key levels that RMD needs to respect. (VIEW LINK)
1 stock mentioned
Michael Gable is managing director of Fairmont Equities. We are a small boutique advisory that uniquely combines both fundamental and technical analysis. As a result, our analysis is featured regularly in the finance media such as the Australian...
No areas of expertise